**FOR ORAL OR POSPRESENTATION (PAUSA) by EMERITUS PROF E D YEBOAH**

**PROSTATE CANCER (PC)- MANAGEMENT OF 669 CASES IN GHANA WEST AFRICA.**

AUTHORS.- YEBOAH E D1,3,HSING AW4,BIRITWUM RB1,TETTEY Y1,MANTE S2,MENSAH JE 1,KYEI M Y1,YARNEY J1,VANDERPUIJE V1,BEECHEM K1,ASANTE K1,AMPADU K1,ADUSEI B2,GEPI ATTEE S1,KLUFIO G O1,LAMPTEY E1,OWOO C1,MARZO A 4,NETTO G 4,YU K4,LI V4,CHOKKALINGHAM A4,CHIA D4,JADDALAH S4,PARTIN A4,THOMPSON I M4,QUARAISHI S M4,ADDO-AYENSU G4,NIWA S4,TARONE R,HOOVER R N4

From .1Department of Surgery,Pathology,Radiooncology,University of Ghana Medical School, and Korle-Bu Teaching Hospital,237 Military Hospital,Accra,3Nyaho Medical Centre,Accra,4NCI/NIH Bethesda USA,5Cancer Protection Institute,California.

OBJECTIVES.Study Clinical incidence of histologically proven PC, TNM stage and management outcomes

METHODS .Case expansion study of PC managed in Accra,abstracted records 2004 -2012.

Diagnosis by history,HoghPSA,physical and abnormal DRE and histologically confirmed by biopsy . With gleason scores(GS) and TNM staged and managed by approved protocols.Organ confined PC by radical prostatectomy(RP),brachytherapy(BRCHY),external beam radiotherapy(EBRT),Hormonal/ Chemotherapy, or surveillance if life expectancy less than 15 years.T3-4M0 treated by hormonal/chemotherapy+/- Total androgen blockade(TAB),BRCHY/EBRT. Metastatic T1-4-M1 is treated by hormonal/chemotherapy +/- TAB.Significant LUTO is treated by alpha blockers,TUIP/TURP.

RESULTS.-There were 669 cases median age 70yrs,median GS 7,organ confined PC 415(62%),T3-4 M0 167(25%),METASTATIC CASES 87(13%).The report on 669 cases were followed for 1-7yrs is as follows.

A.ORGAN CONFINED T1-2 N0 M0 PC- n=415 presentation is asymptomatic .Symptomatic cases 1-20% .treatment regimes

i)RADICAL PROSTATECTOMY – N=92.Open retropubic/prior median PSA 16.1ng/ml,post PSA 0.23ng/ml. RP specimen BPH=3,organ confined 76,positive margins 13.Complications rate (COMP)3-22%.

ii)BRACHYTHERAPY n=70.145 GY,median prior PSA 14.6ng/ml,post PSA 0.59ng/ml.COMP 3-10%

iii) EBRT .no= 155 .70/74GY.Median prior PSA 15.7ng/mlpost PSA 0.54ng/ml.COMP 2-6%

iv)HORMONAL CHEMOTHERAPY +TAB. N= 98 prior median PSA 48.5ng/ml,post PSA 0.6ng/ml.METHODS LHRH analogue /Chemotherapy 41%,stilboesterol 29%,BTO 30%.COMP 4-30%.

v) Surveillance GS 6.prior PSA<8ng/ml.Presentation symptomatic 60%.

All hadneoadjuvant hormonal/chemotherapy +TAB ,LHRH 52%,stilboesterol 12%,BTO36% then

i)Bachytherapy–T3N3,prior PSA 14.6ng/ml ,post PSA 0.11ng/ml

ii)EBRT .no-64.Prior PSA T3 (34%) 32.4ng/ml,T4(2%)64.6ng/ml,Post PSA T3 0.6ng/ml,T4 0.4ng/ml,COMP=2-70%

iii)Hormonal chemotherapyn=103 (T3 24%,T4 38%),LHRH 28%stilboesterol 4%,BTO 30%,COMP 4-35%,Hospitalmortality 26.3%.

C.ADVANCED METASTATIC T1-4 N1-3 M1 n=87,13% median prior PSA 93ng/ml,post PSA 0.4ng/ml.Presentation all symptomatic .RX LHRH 23% ,Stilboesterol 17%,BTO 60%,COMP 20-34%,Hospital mortality 37%

CONCLUSIONS.

Prior to 2000 15.3% organ confined ,T3/T4 32% and metastatic 52%.Improved facilities and skilled teams since 2004 led to organ confined PC 62% curable by RP,brachytherapy or EBRT with longer disease free survival but advanced disease pose challenges for disease control.

REFERENCES

**REFERENCES**

1. A Ruenes Jr. and SM Gueye, “Teaching radical prostatectomy in sub-Saharan Africa”, The Canadian Journal of Urology, vol. 15, no. 1, pp. 3889, 2008.

2. Angwafo FF., “Migration and prostate cancer; an international perspective” J Narl Med Assoc 1998; 159 – 64.

3. BF Morrison, K Coard, G Strachan, R Miller, W Aiken and R Mayhew, “Radical prostatectomy outcomes at the university hospital of the West Indies; 2000 – 2007”, West Indian Medical Journal, vol. 60, no. 1, pp. 68 -72.

4. CF Heyns, M Fisher, A Lecuona, and A van der Merwe, “Prostate cancer among different racial groups in the Western Cape: presenting features and management”, South African Medical journal, vol. 101, no. 4, pp 267 – 270, 2011.

5. EK Wiredu and HB Armah, “Cancer mortality patterns in Ghana: a 10 year review of autopsies and hospital mortality”, BMC Public Health, vol. 6, article 159, 2006.

6. E Yeboah, E Hsing, Y Tetteh et al., “Prostate cancer screening in Ghana”, Urology, vol. 74, supplement 1, no. 4 pp. S200 – S201; 2009.

7. Farcas A et al (2000): “Ethnic and racial differences in prostate cancer incidence and mortality”. Ethn DS 2000; 10; 69 – 75.

8. H Gronberg, “Prostate cancer epidemiology”, The Lancet, vol. 361, no. 9360, pp. 859 – 864, 2003.

9. Hsing AW et al (2000): International trends and patterns of cancer incidence and mortality. Int J cancer 2000; 85; 60 – 7.

10. Hsing AW: “Hormones and prostate cancer; what’s next?” Epidemio/Rev 2000; 23; 42 – 58.

11. IJ Powell, “Epidemiology and pathophysiology of prostate cancer in African-American men”. Journal of Urology, vol. 177, no. 2, pp. 444 -449, 2007.

12. A Eastham, K Kuroiwa, M Ohori et al., “Prognostic significance of location of positive margins in radical prostatectomy specimens”, Urology, vol. 70, no. 5, pp. 965 – 969, 2007.

13. Jamal A, Centrer MM et al “Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology Biomarkers” Prev 2010 Ang 19(8): 1893 – 907.

14. M Jalloh, TM Friebel, …SD Mante, ED Yeboah, “Evaluation of 4,672 routine prostate biopsies performed in 6 African Countries”, 2013 J Afr. Cancer DO1 10.1007/S12558-013-02464Y.

15. MY Kyei, JE Mensah, S Gepi-Attee, D Kwami, K Ampadu, E Asante, GO Klufio, ED Yeboah 2013 – “Outcomes after Radical Prostatectomy in Ghanaians. A Surgeon’s Early Experience” ISRN Urology vol. 2013 Article 1D 832496 p1 – 5.

16. Ogunbiyi JO, Shittu OB: “Increased incidence of prostate cancer in Nigerians” J Natl Ed Assoc 1999; 159 – 64.

17. Osegbe DN: “Prostate cancer in Nigerians facts and non facts”, J Uroll 1997; 157; 1340 – 3.

18. PC Walsh, “Radical Prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debates”, Journal of Urology, vol. 163, no. 6, pp. 1802 – 1807, 2000.

19. R Paul, R Schmid, R B usch et al, “Influence of blood transfusions during radical retropubic prostatectomy on disease outcome” Urology vol. 67, no. 1, pp. 137 – 141, 2006.

20. SE Shirley, CT Escofferey, LA Sargeant, and T Tulloch, “Clinicopathological features of prostate cancer in Jamaican men, “BJU International, vol. 89, no. 4, pp. 390 – 395, 2002.

21. SS Chang, DT Duong, N Wells, EE Cole, JA Smith and MS Cookson, “Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index”, Journal of Urology, vol. 171, no. 5, pp. 1861 – 1865, 2004.

22. WJ Catalona, FG Carvalhal, DE Mager, and DS Smith, “Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies”, Journal of Urology, vol. 162, no. 2, pp. 433 0- 438,1999.

23. Yarney K, Vanderpuije V, Mensah JE, “Clinico-pathologic features and determination of Gleason Score of prostate cancer in Ghanaian men”. Urologic Urology XX p 1078.

24. Yarney K, Vanderpuije V, Mensah JE, “Clinico-pathologic features and determination of Gleason Score of prostate cancer in Ghanaian men”. Urologic Oncologic” 31 (3) 325 -30.

25. Yeboah ED, et al (2002) “Ketoconazole and bisphosphates in advanced hormonal refractory prosate cancer in Ghanaians”, - BJU Intvol 90 Supplement 2 pg 304.

26. Yeboah ED, Mante S, Klufio GO, Bentsi IK, et al (2000): “Correlation of efficacy of digitally guided TRUCUT, transrectal biopsy of prostate (DGTPBX) and ultrasound guided transrectal biopsy of the prostate (TRUSBX) in the diagnosis of cancer of prostate”, BJU Int vol. 86 Supplement 3 Nov. 2000 p10.

27. Rebbeck TM, DevesaSS, ….Yeboah ED et al (2013): “Global Patterns of Prostate cancer incidence, Aggressiveness and Mortality in Men of African Descent”, Prostate Cancer vol 2013 Article ID560857 P1 – 12.